Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 9/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | AKT2 | P31751 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25717304 | 0.88 | MEN1 (0.50) | MEN1KMT2AHTT | |
| SCHEMBL30405805 | 0.88 | MEN1 (0.50) | MEN1KMT2AHTT | |
| Hydrochloric Acid SCHEMBL30406250 | 0.88 | MEN1 (0.49) | MEN1KMT2AHTT | |
| SCHEMBL25717282 | 0.87 | MEN1 (0.42) | GPR183MEN1KMT2AHTTACHE | |
| SCHEMBL31027442 | 0.87 | MEN1 (0.44) | GPR183MEN1KMT2AHTTACHE | |
| SCHEMBL31578660 | 0.83 | MEN1 (0.47) | MEN1KMT2AHTT | |
| SCHEMBL24939735 | 0.79 | MEN1 (0.46) | GPR183MEN1KMT2A | |
| SCHEMBL24940485 | 0.75 | MEN1 (0.48) | GPR183MEN1KMT2A | |
| SCHEMBL24940445 | 0.75 | MEN1 (0.64) | MEN1KMT2A | |
| SCHEMBL25437860 | 0.75 | MEN1 (0.52) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | claimed |
| CN-118647378-A | Inhibitors of Mei Nen protein interaction with MLL | 巴拉疗法公司 | 2024-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | GPR183 2574/4885MEN1 2/4885KMT2A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.